B
Béatrice Laupèze
Researcher at GlaxoSmithKline
Publications - 5
Citations - 355
Béatrice Laupèze is an academic researcher from GlaxoSmithKline. The author has contributed to research in topics: Vaccination & AS03. The author has an hindex of 3, co-authored 5 publications receiving 132 citations.
Papers
More filters
Journal ArticleDOI
The how’s and what’s of vaccine reactogenicity
Caroline Hervé,Béatrice Laupèze,Giuseppe Del Giudice,Arnaud Didierlaurent,Fernanda Tavares Da Silva +4 more
TL;DR: The intent is to provide an overview of reactogenicity after vaccination to help the vaccine community in maintaining confidence in vaccines by promoting vaccination, setting expectations for vaccinees about what might occur after vaccination and reducing anxiety by managing the vaccination setting.
Journal ArticleDOI
Adjuvant Systems for vaccines: 13 years of post-licensure experience in diverse populations have progressed the way adjuvanted vaccine safety is investigated and understood.
TL;DR: A historical perspective on how AS were developed from the angle of the challenges encountered on safety evaluation during clinical development and after licensure is provided, and how these challenges have been met to date are illustrated.
Journal ArticleDOI
Superior antigen-specific CD4+T-cell response with AS03-adjuvantation of a trivalent influenza vaccine in a randomised trial of adults aged 65 and older
Robert B. Couch,José M. Bayas,Covadonga Caso,Innocent N. Mbawuike,Concepción Núñez López,Carine Claeys,Mohamed El Idrissi,Caroline Hervé,Béatrice Laupèze,Lidia Oostvogels,Philippe Moris +10 more
TL;DR: This positive effect of AS03 Adjuvant System on the CD4+ T-cell response to influenza vaccine strains in older adults could confer benefit in protection against clinical influenza disease in this population.
Journal ArticleDOI
Vaccination as a preventative measure contributing to immune fitness.
TL;DR: In this article, the authors discuss the concept of immune fitness and how to potentially build a resilient immune system that could contribute to better health, and argue that vaccines may contribute positively to immune fitness in ways that are only beginning to be understood.
Book ChapterDOI
Novel Technologies to Improve Vaccines for Older Adults.
TL;DR: The recently licensed adjuvanted herpes zoster vaccine shows that immunosenescence need not be a barrier to highly effective vaccination, and that highly effective vaccines for older adults can be achieved with good vaccine design.